Zobrazeno 71 - 80
of 522
pro vyhledávání: ''
Publikováno v:
Clinical Lung Cancer. 21:288-293
The Hoosier Cancer Research Network (HCRN) LUN 14-179 is a phase II trial of consolidation pembrolizumab after concurrent chemoradiation for the treatment of patients with stage III non-small-cell lung cancer (NSCLC). Time to metastatic disease or de
Autor:
Makoto Nishio, Junji Ichinose, Sakae Okumura, Mingyon Mun, Yosuke Matsuura, Yohei Kawaguchi, Masayuki Nakao, Hironori Ninomiya, Katsunori Oikado
Publikováno v:
Clinical Lung Cancer. 21:281-287
To predict the histologic invasiveness of pure GGNs using the maximum CT value.One hundred eighty patients underwent a resection of pure GGNs. On preoperative CT imaging studies, we selected the axial section that showed the densest component of each
Autor:
Mario Miccoli, Iacopo Petrini, Marzia Del Re, Antonio Chella, Marina Chiara Garassino, Giulia Gianfilippo, Daniele Pozzessere, Francesca Mazzoni, Stefania Crucitta, Giuliana Restante, Eleonora Rofi, Romano Danesi, Simona Valleggi
Publikováno v:
Clinical Lung Cancer. 21:232-237
Background Insights into the mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) could provide important information for further patient management, including the choice of second-line treatment. The E
Causes of Death and Hospitalization in Long-term Lung Cancer Survivors: A Population-based Appraisal
Autor:
Betty Ferrell, Geena X. Wu, Dan J. Raz, Virginia Sun, Jae Y. Kim, Philip H.G. Ituarte, Loretta Erhunmwunsee
Publikováno v:
Clinical Lung Cancer. 21:204-213
Introduction Lung cancer survivorship is emerging as an important topic owing to improved survival, but information about health issues among survivors of lung cancer is still lacking. This study used a population dataset to assess causes of death (C
Autor:
Anne C. Melzer, Ping Yang, Pamala A. Jacobson, Camille Robichaux, Abbie Begnaud, Robert A. Kratzke, Constantin F. Aliferis, Nathan Rubin
Publikováno v:
Clin Lung Cancer
American Indians and Alaska Natives experience higher lung cancer mortality than other races in Minnesota. We compared rates of standard-of-care genetic mutation testing in this group compared to non-Native controls. No significant difference was ide
Publikováno v:
Clinical Lung Cancer. 21:195-203
Retrospective studies have shown an increased risk of second primary lung cancer in patients with a history of head and neck cancer (HNC). No population-based study has examined the overall survival (OS) outcomes of patients with second primary non-s
Autor:
Yuanquan Yang, Balazs Halmos, Janaki Sharma, Roman Perez-Soler, Christopher Su, Haiying Cheng, Kenny Ye, Lei Deng, H. Dean Hosgood
Publikováno v:
Clin Lung Cancer
Little is known about the difference between black and non-black patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), particularly regarding survival. We thus characterized the EGFR expression profile, cli
Autor:
Suresh Senan, Norah J. Shire, H. Jiang, Yuanbin Chen, Wenliang Yao, Gabriel Mak, Gyeong Won Lee, Byoung Chul Cho, Isamu Okamoto, Seiji Niho
Publikováno v:
Clinical Lung Cancer, 21(2), e84-e88. Elsevier
Senan, S, Okamoto, I, Lee, G-W, Chen, Y, Niho, S, Mak, G, Yao, W, Shire, N, Jiang, H & Cho, B C 2020, ' Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer : The ADRIATIC Study ', Clinical Lung Cancer, vol. 21, no. 2, pp. e84-e88 . https://doi.org/10.1016/j.cllc.2019.12.006
Senan, S, Okamoto, I, Lee, G-W, Chen, Y, Niho, S, Mak, G, Yao, W, Shire, N, Jiang, H & Cho, B C 2020, ' Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer : The ADRIATIC Study ', Clinical Lung Cancer, vol. 21, no. 2, pp. e84-e88 . https://doi.org/10.1016/j.cllc.2019.12.006
Limited-stage (LS) small-cell lung cancer (SCLC) remains an area of high unmet medical need. The standard-of-care therapy comprises curative-intent platinum-based chemotherapy with concurrent radiotherapy (cCRT), which can be followed by prophylactic
Autor:
Yimei Han, Alexander Howard, Edward S. Kim, William A. Ahrens, James T. Symanowski, Elyssa Kim, Kathryn Dumas, Jennifer L. Ersek
Publikováno v:
Clinical Lung Cancer. 21:160-170
Pulmonary carcinosarcoma (PC) is a rare malignant neoplasm composed of epithelial and mesenchymal components. It accounts for 1% of thoracic cancers and is not fully understood. This study examined Surveillance, Epidemiology, and End Results (SEER) d
Autor:
Virginia Pardo-Marqués, M. Teresa Agulló-Ortuño, Laura Ojeda, Lara Iglesias, Irene Ferrer, Óscar Gómez-Martín, Luis Paz-Ares, Santiago Ponce, Inmaculada García-Ruiz
Publikováno v:
Clinical Lung Cancer. 21:75-85
Background Immunotherapy is a promising cancer treatment, but surrogate biomarkers of clinical efficacy have not been fully validated. The aim of this work was to evaluate several biomarkers as predictors of response to nivolumab monotherapy in patie